Hormonal
Lixisenatide, a GLP-1 receptor agonist, does not reduce the rate of major cardiovascular events in patients with type 2 diabetes and recent acute coronary syndrome compared to placebo.
If you have type 2 diabetes and have recently had a heart event, adding lixisenatide to your treatment plan will not lower your risk of another heart attack, stroke, or cardiovascular death compared to standard care alone. However, it does help lower blood sugar levels and may lead to modest weight loss. It is safe regarding serious adverse events like pancreatitis or cancer, but gastrointestinal issues like nausea are common reasons for stopping the drug.
In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events.
Why this rating
Large-scale, multicenter, randomized, double-blind, placebo-controlled trial (ELIXA) with adequate statistical power.
Source
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al. · New England Journal of Medicine · 2015
DOI 10.1056/nejmoa1509225
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →